HCP
RNTX

Hexagon Capital Partners’s Rein Therapeutics RNTX Stock Holding History

Hexagon Capital Partners’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-213
Closed -$377 – 1818
2025
Q1 		$377 Hold
213
– – ﹤0.01% 1700
2024
Q4 		$490 Hold
213
– – ﹤0.01% 1691
2024
Q3 		$754 Hold
213
– – ﹤0.01% 1365
2024
Q2 		$591 Buy
+213
New +$875 ﹤0.01% 1316

Other funds holding RNTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return

Hexagon Capital Partners's RNTX Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Rein Therapeutics (RNTX) in Q2 2025, closing a stake of 213 shares — an estimated $377 sold.

Hexagon Capital Partners first reported a position in RNTX in Q2 2024 and held it in 4 quarters. The position peaked at $754 in Q3 2024. 36 funds tracked by Wall St. Rank hold RNTX as of Q2 2025.

  • Hexagon Capital Partners reported no remaining Rein Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 213 Rein Therapeutics shares in Q2 2025, an estimated $377.
  • Hexagon Capital Partners first reported a position in Rein Therapeutics in Q2 2024 and held it in 4 quarters.
  • Hexagon Capital Partners's Rein Therapeutics position peaked at $754 in Q3 2024.
  • 36 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.